• Ar
  • Es
Al Mayadeen English

Slogan

  • News
    • Politics
    • Economy
    • Sports
    • Arts&Culture
    • Health
    • Miscellaneous
    • Technology
    • Environment
  • Articles
    • Opinion
    • Analysis
    • Blog
    • Feature
  • Videos
  • Infographs
  • In Pictures
  • • LIVE
News
  • Politics
  • Economy
  • Sports
  • Arts&Culture
  • Health
  • Miscellaneous
  • Technology
  • Environment
Articles
  • Opinion
  • Analysis
  • Blog
  • Feature
Videos
Infographs
In Pictures
  1. Home
  2. News
  3. Europe
  4. New cancer treatment offers hope to patients out of options
Europe

New cancer treatment offers hope to patients out of options

  • By Al Mayadeen English
  • Source: Agencies
  • 22 Aug 2022 09:45

Oncologists in the UK discover that combining immunotherapy with guadecitabine, a novel investigational medicine, can reverse cancer's resistance to immunotherapy.

  • New cancer treatment offers hope to patients out of options.
    New cancer treatment offers hope to patients out of options.

A newly discovered cancer treatment can stop the disease from advancing in patients who are resistant to immunotherapy. 

Immunotherapy is a type of cancer treatment that employs the immune system to target and kill cancer cells. It can save lives when other treatment choices, such as surgery, radiotherapy, or chemotherapy, have failed. Treatment cannot, however, benefit all patients, and some tumors can adapt to resist it.

Oncologists in the United Kingdom have discovered that combining immunotherapy with guadecitabine, a novel investigational medicine, can reverse cancer's resistance to immunotherapy. They discovered that patients who were anticipated to die after exhausted all therapy options lived far longer.

Read next: Almost half of cancer deaths connected to preventable factors: Study

The combination of immunotherapy medicine pembrolizumab and next-generation DNA hypomethylating agent guadecitabine slowed the progression of cancer in more than a third of patients enrolled in the early phase 1 trial. The findings were published in the Journal for ImmunoTherapy of Cancer.

The combination could become an effective weapon against different forms of cancer, experts revealed at the Institute of Cancer Research and Royal Marsden NHS foundation trust. 

Patients in the trial, from the Royal Marsden and University College London hospital, included those with lung, breast, prostate, and bowel cancer.

Treatment 

The study used pembrolizumab and guadecitabine to treat 34 cancer patients, 30 of whom had their tumors analyzed for immune activity and cancer growth. Every three weeks for three years, they had an injection of guadecitabine for four days in a row – and pembrolizumab on the first of those days.

Pembrolizumab is an immune checkpoint inhibitor drug that has already proved successful in treating a range of cancers, including lung and skin cancers. However, tumors can develop resistance to it and some patients who initially benefit will eventually get sicker.

Read next: AI tool accurately predicts tumor regrowth in cancer patients

The study lead, Anna Minchom, a clinical scientist at the Institute of Cancer Research and a consultant medical oncologist at the Royal Marsden, said: “Immunotherapy has shown amazing promise in cancer care over the last decade, but it doesn’t work well in all cancers and cancers can often become resistant. This combination might be a way to target their cancer even after it has stopped responding to immunotherapy.”

Guadecitabine may help overcome this resistance, doctors, researchers and scientists involved in the trial have discovered.

37% record no tumor progression 

The tumor stopped progressing in 37% of the 30 patients whose cancer activity was studied, during 24 weeks or more. Prior to the experiment, three-fifths of the cohort (60%) were resistant to immunotherapy. Almost four in ten (39%) did not become ill as a result of the drug combination.

The new treatment could help lung cancer patients. Of those resistant to immunotherapy, half had their disease controlled for 24 weeks or more.

A patient from Dorset, Alison Sowden, was diagnosed with lung cancer four years ago and was told she had a year to live, but then received pembrolizumab for three years. She is now free of cancer.

“I know there is a chance that my cancer may come back and develop resistance to treatment, so it is reassuring to know research efforts aiming to reverse cancer’s resistance to immunotherapy are under way,” she said.

“I hope this new experimental drug combination will eventually make it to the clinic and help people who have developed resistance to pembrolizumab.”

  • Cancer
  • United Kingdom

Trending Now

All
The viruses would help humanity make strides in the combat against cancer

Researches using 'bugs as drugs' for breast, prostate cancer

Most Read

Ukrainian President Volodymyr Zelensky speaks at a press conference on 25, February, 2022. (AFP)

Kiev unable to launch counteroffensive: Zelensky

  • Europe
  • 25 Mar
Europe's move has only increased Putin’s esteem outside the West -- but estimation of Europe’s political nous and understanding of Russia, however, is sharply diminished.

Lawfare Comes into Fashion: The New Geo-political ‘Rack’

  • Analysis
  • 25 Mar
President Joe Biden listens as German Chancellor Olaf Scholz speaks during a meeting in the Oval Office of the White House in Washington, Friday, March 3, 2023 (AP).

Hersh: Nord Stream explosion decision possibly 'anger' or 'punishment

  • US & Canada
  • 25 Mar
Crewmen enter Bradley fighting vehicles at a US military base at an undisclosed location in Northeastern Syria, on November 11, 2019 (AP)

US occupation bases under fire in Syria for second day in a row

  • MENA
  • 24 Mar

Read this

All
SDF and US troops in occupied Al Hasakah, Syria. (Reuters)
MENA

ISIS stole US arms in Syria, Iraq: The Intercept

  • Today
US military vehicle is seen on a patrol in the countryside near the town of Qamishli, Syria, December 4, 2022 (AP)
MENA

6 US occupation troops suffer 'traumatic brain injuries' in Syria: DoD

  • 30 Mar
A woman walks by a money exchange shop decorated with different countries currency banknotes at Central, a business district in Hong Kong, Aug. 6, 2019 (AP Photo/Kin Cheung)
Europe

New BRICS currency underway: State Duma Deputy Chairman

  • 30 Mar
President Joe Biden speaks alongside Secretary of State Antony Blinken during a Summit for Democracy virtual plenary in the South Court Auditorium on the White House campus, March 29, 2023, in Washington, DC, United States (AP)
Latin America

Brazil not to sign Summit for Democracy declaration against Russia

  • 30 Mar
Al Mayadeen English

Al Mayadeen is an Arab Independent Media Satellite Channel.

All Rights Reserved

  • Privacy Policy
  • About Us
  • Contact Us
  • Authors
Android
iOS